
|Videos|January 27, 2022
Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the interview, Lepor discussed some of the major trends in the ASCVD and LDL-C management treatment landscape this year.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tirzepatide to Cut CV Risk in Type 2 Diabetes
2
August 2026 in Oncology: FDA Approvals and Phase 3 Data Reshape Treatment Across Tumor Types
3
New Lipid Drugs and What Pharmacists Need to Know
4
FDA Approves Ustekinumab Injection for Pediatric Ulcerative Colitis, Expanding IBD Options for Children
5


































































































